171 related articles for article (PubMed ID: 25296077)
1. Study on adherence to capecitabine among patients with colorectal cancer and metastatic breast cancer.
Figueiredo Junior AG; Forones NM
Arq Gastroenterol; 2014; 51(3):186-91. PubMed ID: 25296077
[TBL] [Abstract][Full Text] [Related]
2. Capecitabine non-adherence: exploration of magnitude, nature and contributing factors.
Bhattacharya D; Easthall C; Willoughby KA; Small M; Watson S
J Oncol Pharm Pract; 2012 Sep; 18(3):333-42. PubMed ID: 22298660
[TBL] [Abstract][Full Text] [Related]
3. Adherence and persistence with oral adjuvant chemotherapy in older women with early-stage breast cancer in CALGB 49907: adherence companion study 60104.
Partridge AH; Archer L; Kornblith AB; Gralow J; Grenier D; Perez E; Wolff AC; Wang X; Kastrissios H; Berry D; Hudis C; Winer E; Muss H
J Clin Oncol; 2010 May; 28(14):2418-22. PubMed ID: 20368559
[TBL] [Abstract][Full Text] [Related]
4. Capecitabine and radiotherapy as neoadjuvant treatment for rectal cancer.
Ben-Josef E
Am J Clin Oncol; 2007 Dec; 30(6):649-55. PubMed ID: 18091061
[TBL] [Abstract][Full Text] [Related]
5. How the new oral antineoplastics affect nursing practice: capecitabine serves to illustrate.
Szetela AB; Gibson DE
Am J Nurs; 2007 Dec; 107(12):40-8; quiz 48-9. PubMed ID: 18049060
[TBL] [Abstract][Full Text] [Related]
6. A phase II Study of the global dose and schedule of capecitabine in Japanese patients with metastatic colorectal cancer.
Hyodo I; Shirao K; Doi T; Hatake K; Arai Y; Yamaguchi K; Tamura T; Takemiya S; Takiuchi H; Nakagawa K; Mishima H
Jpn J Clin Oncol; 2006 Jul; 36(7):410-7. PubMed ID: 16825251
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of quality of life in patients with metastatic colorectal cancer treated with capecitabine.
Segalla JG; Van Eyll B; Federico MH; Skare NG; Franke FA; Perdicaris MR; Filho Ude P; Gampel O; Cabral S; Ribeiro Rde A
Clin Colorectal Cancer; 2008 Mar; 7(2):126-33. PubMed ID: 18501072
[TBL] [Abstract][Full Text] [Related]
8. Oral capecitabine (Xeloda) in cancer treatment.
Doyle DP; Engelking C
Nurse Pract; 2007 Feb; 32(2):18-21. PubMed ID: 17264789
[No Abstract] [Full Text] [Related]
9. A pilot phase II study of capecitabine in advanced or recurrent colorectal cancer.
Kondo Y; Terashima M; Sato A; Taguchi T
Jpn J Clin Oncol; 2004 Apr; 34(4):195-201. PubMed ID: 15121755
[TBL] [Abstract][Full Text] [Related]
10. Over compliance with capecitabine oral chemotherapy.
Allen J; Williamson S
Int J Clin Pharm; 2014 Apr; 36(2):271-3. PubMed ID: 24532364
[TBL] [Abstract][Full Text] [Related]
11. Enhancing adherence to capecitabine chemotherapy by means of multidisciplinary pharmaceutical care.
Simons S; Ringsdorf S; Braun M; Mey UJ; Schwindt PF; Ko YD; Schmidt-Wolf I; Kuhn W; Jaehde U
Support Care Cancer; 2011 Jul; 19(7):1009-18. PubMed ID: 20552377
[TBL] [Abstract][Full Text] [Related]
12. Over-adherence to capecitabine: a potential safety issue in breast and colorectal cancer patients.
Le Saux O; Bourmaud A; Rioufol C; Colomban O; Guitton J; Schwiertz V; Regnier V; You B; Ranchon F; Maraval-Gaget R; Girard P; Chauvin F; Freyer G; Tod M; Henin E; Trillet-Lenoir V
Cancer Chemother Pharmacol; 2018 Aug; 82(2):319-327. PubMed ID: 29948022
[TBL] [Abstract][Full Text] [Related]
13. [Validation of a questionnaire assessing patients' adherence and skill level of management for oral capecitabine treatment].
Baudot A; Oriol M; Tinquaut F; Moine V; Moriceau G; Muron T; Pacaut C; Collard O; Jacquin JP; Saban-Roche L; Bosacki C; Regnier-Denois V; Chauvin F; Bourmaud A
Bull Cancer; 2016 Mar; 103(3):241-51. PubMed ID: 26917467
[TBL] [Abstract][Full Text] [Related]
14. Multicenter phase II study of oral capecitabine plus irinotecan as first-line chemotherapy in advanced colorectal cancer: a Korean Cancer Study Group trial.
Kim TW; Kang WK; Chang HM; Park JO; Ryoo BY; Ahn JS; Zang DY; Lee KH; Kang YK; Kim SR; Kim HK;
Acta Oncol; 2005; 44(3):230-5. PubMed ID: 16076694
[TBL] [Abstract][Full Text] [Related]
15. Clinical and cost-effectiveness of capecitabine and tegafur with uracil for the treatment of metastatic colorectal cancer: systematic review and economic evaluation.
Ward S; Kaltenthaler E; Cowan J; Brewer N
Health Technol Assess; 2003; 7(32):1-93. PubMed ID: 14604497
[TBL] [Abstract][Full Text] [Related]
16. Adherence with oral chemotherapy: results from a qualitative study of the behaviour and representations of patients and oncologists.
Regnier Denois V; Poirson J; Nourissat A; Jacquin JP; Guastalla JP; Chauvin F
Eur J Cancer Care (Engl); 2011 Jul; 20(4):520-7. PubMed ID: 20649809
[TBL] [Abstract][Full Text] [Related]
17. Patient-reported outcomes from EMILIA, a randomized phase 3 study of trastuzumab emtansine (T-DM1) versus capecitabine and lapatinib in human epidermal growth factor receptor 2-positive locally advanced or metastatic breast cancer.
Welslau M; Diéras V; Sohn JH; Hurvitz SA; Lalla D; Fang L; Althaus B; Guardino E; Miles D
Cancer; 2014 Mar; 120(5):642-51. PubMed ID: 24222194
[TBL] [Abstract][Full Text] [Related]
18. Preoperative chemoradiotherapy for rectal cancer: a comparison between intravenous 5-fluorouracil and oral capecitabine.
Ramani VS; Sun Myint A; Montazeri A; Wong H
Colorectal Dis; 2010 Aug; 12 Suppl 2():37-46. PubMed ID: 20618366
[TBL] [Abstract][Full Text] [Related]
19. Dramatic response of recalcitrant warts as a side effect of colorectal cancer treatment with oral capecitabine.
Bel B; Lorton MH; Darut-Jouve A; Vabres P
Eur J Dermatol; 2011; 21(5):789-90. PubMed ID: 21700544
[No Abstract] [Full Text] [Related]
20. The role of capecitabine in first-line treatment for patients with metastatic breast cancer.
Gelmon K; Chan A; Harbeck N
Oncologist; 2006; 11 Suppl 1():42-51. PubMed ID: 16971739
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
